Skip to main content

Mangalam Drugs and Organics Ltd

Stage 1 · Basing · week 5

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. More about the company

₹33.1
+3.86% today
₹52 Cr · Micro cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-54.5%
₹23.8 lo₹72.8 hi
54.5% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 5
1w13w26w
Week 5 — early base, needs time
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
7.9%
200 DMA: ₹30.7 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.35x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
→
MA20 flat · +0.3% vs MA50 +6.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+10.2%
3M
+22.9%
6M
+9.4%
YTD
+37.4%
1Y
-54.2%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
Sector has 77 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Industry has 61 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-11 → 2026-10-07
S4 22w
S2 18w
S4 20w
S4 25w
S4 22w
2023-07-112026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 5w → S1 2w → S4 22w → S1 3w → S2 6w → S3 5w → S4 5w → S1 2w → S2 18w → S3 11w → S4 20w → S1 12w → S4 25w → S1 5w → S4 22w → S1 4w current
Total tracked: 168 weeks across 16 stage runs.
Scan Membership
Breakout Watch
Latest: 2024-07-05
2 appearances in last 60 days. First seen: 2024-02-21.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S1
Wk 5 · Vol 1.35x
2026-10-06S1
Wk 4 · Vol 0.88x
2026-10-05S1
Wk 4 · Vol 0.92x
2026-10-01S1
Wk 4 · Vol 0.61x
2026-09-30S1
Wk 4 · Vol 0.76x
2026-09-29S1
Wk 4 · Vol 0.56x
2026-09-28S1
Wk 3 · Vol 0.64x
2026-09-25S1
Wk 3 · Vol 0.43x
2026-09-24S1
Wk 3 · Vol 0.62x
2026-09-23S1
Wk 3 · Vol 0.72x
2026-09-22S1
Wk 3 · Vol 0.90x
2026-09-21S1
Wk 2 · Vol 2.18x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹30
200 DMA
₹30.7
52W High
₹72.8
52W Low
₹23.8
5D Low
₹29.2
Resistance levels (recent highs)
20d High
₹36.5
60d High
₹36.5
120d High
₹36.5
250d High
₹72.7
Next resistance
+10.2%
to 20d High
ROE
-35.2%
Profit margin -19.1%
About this companyHealth Care· Pharmaceuticals

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.